B
BMRN icon

Birchbrook’s BioMarin Pharmaceuticals BMRN Stock Holding History

Birchbrook’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-55
Closed -$3.87K – 294
2024
Q3 		$3.87K Sell
55
-7,948
-99% -$664K ﹤0.01% 223
2024
Q2 		$659K Sell
8,003
-309
-4% -$25.7K 0.4% 45
2024
Q1 		$726K Buy
8,312
+395
+5% +$35.4K 0.43% 43
2023
Q4 		$763K Buy
+7,917
New +$700K 0.5% 43

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Birchbrook's BMRN Position: Q4 2024 in Review

Birchbrook sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 55 shares — an estimated $3.87K sold.

Birchbrook first reported a position in BMRN in Q4 2023 and held it in 4 quarters. The position peaked at $763K in Q4 2023. 544 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Birchbrook reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Birchbrook sold 55 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $3.87K.
  • Birchbrook first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Birchbrook's BioMarin Pharmaceuticals position peaked at $763K in Q4 2023.
  • 544 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Birchbrook's 13F filing for Q4 2024, filed 10 Jun 2025.